Table 1 |
|||||||
|
Description of studies included in meta-analysis. |
|||||||
|
Author (year) |
Country |
Reference Test |
Blinded to reference test? |
Sample |
Sample size (# resistant / # sensitive) |
Sensitivity (95% CI) |
Specificity (95% CI) |
|
|
|||||||
|
Ahmad (2002) |
Kuwait |
BACTEC 460 |
Not Specified |
Isolate |
29/12 |
0.97 (.82–1.0) |
1.0 (.74–1.0) |
|
De Oliveira (1998) |
Brazil |
Proportion |
Not Specified |
Isolate |
113/15 |
0.97 (.92–.99) |
1.0 (.78–1.0) |
|
Gamboa (1998) |
Spain |
BACTEC 460 |
Not Specified |
Isolate |
46/13 |
1.0 (.92–1.0) |
1.0 (.75–1.0) |
|
Hirano (1999) |
Japan |
Proportion |
Not Specified |
Isolate |
90/26 |
0.92 (.85–.97) |
1.0 (.87–1.0) |
|
Johansen (2003) |
Denmark |
BACTEC 460 |
Not Specified |
Isolate |
35/24 |
0.97 (.85–1.0) |
1.0 (.86–1.0) |
|
Jureen (2004) |
Sweden |
BACTEC 460 |
Not Specified |
Isolate |
27/26 |
1.0 (.87–1.0) |
0.92 (.75–.99) |
|
Lemus (2004) |
Belgium |
BACTEC 460, Proportion |
Yes |
Isolate |
10/10 |
1.0 (.69–1.0) |
1.0 (.69–1.0) |
|
Rossau (1997) |
Belgium |
Proportion |
Not Specified |
Isolate |
203/61 |
0.98 (.95–.1.0) |
1.0 (.94–1.0) |
|
Sintchenko (1999) |
Australia |
BACTEC 460 |
Not Specified |
Isolate |
22/11 |
0.96 (.77–1.0) |
1.0 (.72–1.0) |
|
Somoskovi (2003) |
USA |
Proportion |
Not Specified |
Isolate |
64/37 |
0.95 (.87–.99) |
1.0 (.91–1.0) |
|
Srivastava (2004) |
India |
MIC |
Not Specified |
Isolate |
45/10 |
0.82 (.68–.92) |
1.0 (.69–1.0) |
|
Tracevska (2002) |
Latvia |
BACTEC 460 |
Not Specified |
Isolate |
34/19 |
1.0 (.90–1.0) |
1.0 (.82–1.0) |
|
Traore (2000) |
Belgium |
Proportion |
Not Specified |
Isolate |
266/145 |
0.99 (.96–1.0) |
1.0 (.98–1.0) |
|
Watterson (1998) |
England |
BACTEC 460, Proportion |
Not Specified |
Isolate |
16/16 |
1.0 (.80–1.0) |
0.94 (.70–1.0) |
|
De Beenhouwer (1995) |
Belgium |
Proportion |
Not Specified |
Clinical Specimen |
21/46 |
0.91 (.70–1.0) |
1.0 (.92–1.0) |
|
Gamboa (1998) |
Spain |
BACTEC 460 |
Not Specified |
Clinical Specimen |
46/13 |
0.98 (.89–1.0) |
1.0 (.75–1.0) |
|
Johansen (2003) |
Denmark |
BACTEC 460 |
Not Specified |
Clinical Specimen |
26/21 |
1.0 (.87–1.0) |
1.0 (.84–1.0) |
|
Watterson (1998) |
England |
BACTEC 460, proportion |
Yes |
Clinical Specimen |
10/24 |
0.80 (.44–.98) |
1.0 (.86–1.0) |
|
|
|||||||
|
Morgan et al. BMC Infectious Diseases 2005 5:62 doi:10.1186/1471-2334-5-62 |
|||||||
